For the quarter ended June 2024, Ionis Pharmaceuticals (IONS) reported revenue of $225 million, up 19.7% over the same period last year. EPS came in at -$0.45, compared to -$0.60 in the year-ago quarter. The reported revenue represents a surprise of +52.56% over the Zacks Consensus Estimate of $147.49 million. With the consensus EPS estimate being -$0.95, the EPS surprise was +52.63%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...